Pharmacodynamic Evaluation of Hybrid in situ Gelling system in a Rabbit model of Bacterial Conjunctivitis

Abstract

This study evaluates the pharmacodynamic efficacy of a hybrid in situ gelling system (OPT-07-1) containing Moxifloxacin for treating bacterial conjunctivitis induced by Staphylococcus aureus in a rabbit model. The study groups included untreated rabbits, those treated with a marketed formulation (thrice daily), and those treated with the optimized formulation (twice daily). Clinical signs—redness, inflammation, and tear score—were assessed over five days. Results showed significant improvement in the treated groups, with the optimized formulation providing comparable outcomes to the marketed product despite reduced dosing frequency. The optimized system's prolonged precorneal retention and enhanced penetration contributed to its effectiveness. These findings suggest that the hybrid in situ gel is a promising therapeutic option for ocular infections.